Nicotine patches have become one of the most talked-about ideas in long COVID patient communities. People share stories of brain fog lifting or energy returning within days. Others report no change, or feeling worse.
Here’s what the research actually shows, what it doesn’t, and what to weigh before considering it.
Where the idea came from
Early in the pandemic, researchers noticed that part of the SARS-CoV-2 spike protein resembles sections of certain snake toxins known to bind nicotinic acetylcholine receptors. These receptors are found throughout the nervous and immune systems. They help regulate:
- nerve signaling,
- muscle function,
- inflammation, and
- the “rest and digest” side of the autonomic nervous system.
The hypothesis goes like this: if spike protein interferes with these receptors, some long COVID symptoms (brain fog, fatigue, autonomic problems) could follow. Nicotine binds these same receptors strongly, so it might displace that interference.
Some early reports also suggested smokers were underrepresented among hospitalized COVID patients. Later and larger analyses generally found smoking associated with worse COVID outcomes, so that observation is no longer considered support for the idea.
The long COVID evidence: case reports
The best-known publication is a 2023 paper by Marco Leitzke in Bioelectronic Medicine. It laid out the receptor hypothesis and described four patients with post-COVID syndrome who used low-dose nicotine patches. The patients reported improvements in fatigue, cognitive symptoms, and other complaints, in some cases within days.
That paper is what brought nicotine into the long COVID conversation. It is also the most important thing to understand about the evidence:
- Four patients is a case series, not a trial.
- There was no control group, so the natural ups and downs of long COVID and the placebo effect can’t be separated from a real effect.
- Positive stories are more likely to be shared than neutral or negative ones, both in publications and online.
The controlled trial evidence
A randomized, double-blind, placebo-controlled trial did test nicotine patches in COVID, though not in long COVID. Labro et al. (Intensive Care Medicine, 2022) gave nicotine or placebo patches to 218 critically ill patients on mechanical ventilation. Nicotine did not reduce 28-day mortality, and the authors concluded there was no indication for nicotine in that setting.
That trial studied acute critical illness, which is very different from long COVID, so it doesn’t settle the long COVID question. It does show that when the receptor hypothesis was put to a rigorous test in COVID, it didn’t produce the hoped-for result.
As of September 2026, we were unable to find a completed, published randomized controlled trial of nicotine patches specifically for long COVID.
What to weigh before considering nicotine
Nicotine is a pharmacologically active drug. Being available over the counter for smoking cessation doesn’t make it risk-free for other uses, particularly in people who don’t smoke.
- Heart rate and blood pressure. Nicotine raises both. That matters for people with long COVID, many of whom already have a racing heart on standing. See our page on POTS after COVID.
- Dependence. Nicotine is addictive, even in patch form.
- Common side effects: nausea, dizziness, headache, sleep disturbance, vivid dreams, and skin irritation. These can be more pronounced in non-smokers.
- People who should not use it without specific medical guidance: anyone who is pregnant or breastfeeding, and people with heart disease, heart rhythm disorders, uncontrolled high blood pressure, or a history of stroke. It should not be used by anyone under 18.
- Medication interactions. Discuss any use with the clinician managing your medications.
The bottom line
The nicotine hypothesis for long COVID is biologically interesting. It rests on a plausible receptor mechanism and a small number of encouraging case reports. It has not been confirmed by controlled trials in long COVID, and nicotine carries real risks, especially for the cardiovascular symptoms common in this condition.
If you’re considering it, have that conversation with a clinician who knows your full history rather than starting on your own.
Serving Oklahoma City, Tulsa, and all of Oklahoma
Venturis Clinic sees patients with long COVID from Oklahoma City and surrounding areas, including Tulsa, and from across Oklahoma. Learn how we approach the whole picture on our Long COVID Treatment in Oklahoma City page, or book a free 15-minute discovery call.
Frequently asked questions
Do nicotine patches cure long COVID? There is no evidence that they cure long COVID. The current evidence consists mainly of a small number of uncontrolled case reports.
Why do some people say it helped them? Some people may genuinely respond. But without controlled trials, individual improvements can’t be separated from natural fluctuation or placebo effects.
Is it safe if I don’t smoke? Nicotine has real effects on heart rate, blood pressure, and sleep, and it is addictive. Non-smokers should not start it without guidance from a clinician who knows their history.
Are there clinical trials underway? Research interest continues. Check ClinicalTrials.gov for current studies.
This page is an educational review of published research. It is not a recommendation to use nicotine and is not a substitute for individual evaluation.
By Alvin Philipose, DC (Ret.)
Sources
- Leitzke M. Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? Bioelectronic Medicine. 2023;9:2. doi:10.1186/s42234-023-00104-7
- Labro G, et al. Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Medicine. 2022. PMID: 35676335
- Changeux JP, et al. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Comptes Rendus Biologies. 2020;343(1):33–39.
